Dexrazoxane for treating antitumor-induced cardiotoxicity

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 31/496 (2006.01) A61P 9/00 (2006.01) A61P 35/00 (2006.01) C07K 16/32 (2006.01)

Patent

CA 2467229

The present invention relates to a method for treating a cancer, which comprises administering a therapeutically effective amount of trastuzumab alone or in association with an anthracycline to a patient in need thereof, in combination with an amount of dexrazoxane effective to ameliorate cardiotoxicity.

L'invention concerne une méthode de traitement d'un cancer consistant à administrer une quantité efficace sur le plan thérapeutique de trastuzumab, seul ou associé à une anthracycline, de manière à traiter un patient nécessitant un tel traitement, conjointement avec une quantité de dexrazoxane permettant d'améliorer la cardiotoxicité.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Dexrazoxane for treating antitumor-induced cardiotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dexrazoxane for treating antitumor-induced cardiotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dexrazoxane for treating antitumor-induced cardiotoxicity will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1876011

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.